ESTEVE laboratories has reached an agreement with Astrazeneca to market in Spain as of June the Edistide (Dapagliflozina) and EByMECT (Dapagliflozine and Metformin), indicated for the treatment of type 2 diabetes type 2 in adult patients.
Edistide is an oral antidiabetic indicated in monotherapy in metformin intolerant patients.Its active substance, dapagliflozine, reduces the reabsorption of glucose filtered in the kidney causing the elimination of glucose by urine and, consequently, reducing blood glucose levels in blood plasma.
EBYMECT is another oral antidiabetic that combines dapagliflozine with metformin and can be used in patients not properly controlled with the maximum tolerated dose of metformin in monotherapy or in those that are already being treated with the combination of dapagliflozine and metformin in separate tablets.
Both medications can be used in combination with other hypoglycemic drugs, including insulin, when they, together with diet and exercise, do not achieve adequate glycemic control.
"Our agreement with Esteve is the clear reflection of our commitment to Spain and with national partners. We are convinced that with its broad expertise in the Spanish market, their knowledge in this area and that they share our passion for science, we will continue to improve theQuality of life of patients with diabetes, "said Rodrigo Gribble, director of the Cardiometabolism Business Unit of Astrazeneca Spain.
For his part, Joe Sullivan, general director of Esteve Farma, declares that "the alliance with Astrazeneca allows us to continue to put the most novel treatments in diabetes available to professionals and patients. In addition, it will also further reinforce our activities in thisTherapeutic area, which is a priority for the company. "